Laura Fletcher
Director/Board Member chez Stratosvir Ltd.
Profil
Prior to joining DSV, Laura was Associate Director of Cancer Research UK’s Commercial Partnerships team, heading the Strategic Alliances function which drives the charity’s strategic drug discovery and platform relationships with a range of commercial partners.
Her other experience at CRUK and Cancer Research Technology over 14 years included transacting a wide range of significant license, collaboration and spin out deals.
She holds a 1st class degree in Biochemistry and a PhD in cell signalling from the University of Bristol and has additionally worked in academic and commercial research roles in the US and the UK.
Postes actifs de Laura Fletcher
| Sociétés | Poste | Début |
|---|---|---|
Stratosvir Ltd.
 Stratosvir Ltd. Miscellaneous Commercial ServicesCommercial Services Stratosvir Ltd. is a company based in Ingatestone, UK. Christopher Graeme Ullman has been the CEO of the British company since 2021. | Director/Board Member | 01/04/2021 |
Deep Science Ventures Ltd.
 Deep Science Ventures Ltd. Investment ManagersFinance Deep Science Ventures Ltd. (Deep Science Ventures) is a venture capital firm founded 2016 by Mark Hammond and Dominic Falcão. The firm is headquartered in Essex, United Kingdom. | Private Equity Investor | 01/01/2021 |
Neobe Therapeutics Ltd.
 Neobe Therapeutics Ltd. BiotechnologyHealth Technology Neobe Therapeutics Ltd. is a British biotechnology company founded in 2021. The company is based in Cambridge, UK and engages in research and experimental development in the biotechnology field. | Director/Board Member | 14/04/2021 |
Anciens postes connus de Laura Fletcher
| Sociétés | Poste | Fin |
|---|---|---|
Cellinta Ltd.
 Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Director/Board Member | 31/12/2020 |
ProXara Biotechnology Ltd.
 ProXara Biotechnology Ltd. Pharmaceuticals: MajorHealth Technology ProXara Biotechnology Limited is a recently-formed biotechnology company whose mission is to be a world leader in the development of novel therapeutically-relevant cell-based and in-vitro high throughput screens for drug discovery in the oncology field. The Company was founded by Professor Jeremy Tavaré in the Department of Biochemistry at the University of Bristol and was incorporated in March 2001. The company is supported by an experienced and entrepreneurial management team. ProXara has received funding from the Sulis Seedcorn Fund Partnership Limited, Catalyst BioMedica, The Wellcome Trust and private sources. Its premises are currently in the School of Medical Sciences in the University of Bristol. ProXara has established a portfolio of novel cell-based and in-vitro assays against important intra-cellular targets in cancer (primarily breast and prostate) for screening against both internal and customer compound collections. Breast and prostate cancers are the most prevalent malignancies in women and men respectively, and the second highest cause of cancer deaths. The company's technologies will allow the discovery of drugs with a completely novel mode of action against relevant and validated targets. ProXara is currently undertaking optimization of a series of proprietary drug-like molecules which could provide a novel route for the treatment of cancer. | Founder | - |
Formation de Laura Fletcher
| University of Bristol | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
ProXara Biotechnology Ltd.
ProXara Biotechnology Ltd. Pharmaceuticals: MajorHealth Technology ProXara Biotechnology Limited is a recently-formed biotechnology company whose mission is to be a world leader in the development of novel therapeutically-relevant cell-based and in-vitro high throughput screens for drug discovery in the oncology field. The Company was founded by Professor Jeremy Tavaré in the Department of Biochemistry at the University of Bristol and was incorporated in March 2001. The company is supported by an experienced and entrepreneurial management team. ProXara has received funding from the Sulis Seedcorn Fund Partnership Limited, Catalyst BioMedica, The Wellcome Trust and private sources. Its premises are currently in the School of Medical Sciences in the University of Bristol. ProXara has established a portfolio of novel cell-based and in-vitro assays against important intra-cellular targets in cancer (primarily breast and prostate) for screening against both internal and customer compound collections. Breast and prostate cancers are the most prevalent malignancies in women and men respectively, and the second highest cause of cancer deaths. The company's technologies will allow the discovery of drugs with a completely novel mode of action against relevant and validated targets. ProXara is currently undertaking optimization of a series of proprietary drug-like molecules which could provide a novel route for the treatment of cancer. | Health Technology |
Deep Science Ventures Ltd.
Deep Science Ventures Ltd. Investment ManagersFinance Deep Science Ventures Ltd. (Deep Science Ventures) is a venture capital firm founded 2016 by Mark Hammond and Dominic Falcão. The firm is headquartered in Essex, United Kingdom. | Finance |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Finance |
Stratosvir Ltd.
Stratosvir Ltd. Miscellaneous Commercial ServicesCommercial Services Stratosvir Ltd. is a company based in Ingatestone, UK. Christopher Graeme Ullman has been the CEO of the British company since 2021. | Commercial Services |
Neobe Therapeutics Ltd.
Neobe Therapeutics Ltd. BiotechnologyHealth Technology Neobe Therapeutics Ltd. is a British biotechnology company founded in 2021. The company is based in Cambridge, UK and engages in research and experimental development in the biotechnology field. | Health Technology |
